Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 146 results found. Search for [ Gilead sciences ]

Results 1 to 21 of 146
PB Jayakumar
November 18, 2020
Cipla will sell these kits across 25 markets in Asia, Middle-East and North Africa, Latin America, EU and Australia


Reuters
November 9, 2020
Remdesivir was developed by US drugmaker Gilead Sciences, which cut its 2020 revenue forecast last month, citing lower-than-expected demand and difficulty in predicting sales of treatment


BusinessToday.In
October 26, 2020
Gold, Silver prices today: Gold, viewed as a hedge against inflation and currency debasement has risen over 25% this year, supported by unprecedented monetary stimulus from major central banks


BusinessToday.In
October 26, 2020
India Stock Market Highlights Today: Reliance Industries, followed by Tata Steel, Bajaj Finance, Asian Paints, M&M, ICICI Bank and Bajaj Finserv were among the top laggards in the Sensex pack today. On the other hand, IndusInd Bank, Nestle India, PowerGrid and L&T were among the gainers


BusinessToday.In
October 17, 2020
India participated in the trials too. In a statement issued on Friday, ICMR concluded the same and said there were no benefits of remdesivir in any of the patients


Reuters
October 16, 2020
The American company said the data appeared inconsistent, the findings were premature and that other studies had validated the drug's benefits


BusinessToday.In
October 16, 2020
The WHO said that the Solidarity trial looked at the effects of these treatments on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalised patients


Reuters
October 14, 2020
Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc that he received for his COVID-19, as tantamount to a cure in a video he posted last week


PB Jayakumar
October 8, 2020
Cipla's research and development department is working on a couple of therapies that can be used in the treatment of COVID-19 and it could consider entering into marketing collaborations with companies that are currently developing vaccines for COVID-19


Reuters
October 8, 2020
Several European countries have said they are experiencing shortages of the drug, whose global stock has been secured almost entirely by the United States


Joe C Mathew
October 7, 2020
Parallel to the WTO proposal, SJM wants India to initiate measures under Section 66 of the Patents Act for the cancelation of the patent on Remdesivir


Associated Press
October 4, 2020
Donald Trump offered his own assessment of his status Saturday evening in a video from his hospital suite, saying he was beginning to feel better and hoped to \"be back soon.\"


Reuters
October 4, 2020
A White House team of doctors said on Saturday morning that Trump's condition was improving and that he was already talking about returning to the White House


Reuters
September 24, 2020
The U.S. Department of Justice said on Wednesday the settlement resolves allegations that Gilead improperly used the Caring Voice Coalition as a conduit to cover thousands of patients' co-payment obligations


Reuters
September 13, 2020
A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner


Reuters
September 12, 2020
The Food and Drug Administration has allowed more liberal remdesivir use, but 6 out of 8 major hospital systems contacted by Reuters said they were not using it for moderate cases


BusinessToday.In
September 9, 2020
DCGI has approved Remdesivir for \"restricted emergency use\" in India for treatment of COVID-19 patients hospitalised with severe symptoms


PB Jayakumar
August 13, 2020
Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical


Reuters
August 13, 2020
Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients


PTI
August 8, 2020
The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement


PAGES 1 OF 8  12345